Skip to Content
Merck

Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy.

Molecular therapy : the journal of the American Society of Gene Therapy (2019-10-13)
Kristin L Gardiner, Artur V Cideciyan, Malgorzata Swider, Valérie L Dufour, Alexander Sumaroka, András M Komáromy, William W Hauswirth, Simone Iwabe, Samuel G Jacobson, William A Beltran, Gustavo D Aguirre
ABSTRACT

The form of hereditary childhood blindness Leber congenital amaurosis (LCA) caused by biallelic RPE65 mutations is considered treatable with a gene therapy product approved in the US and Europe. The resulting vision improvement is well accepted, but long-term outcomes on the natural history of retinal degeneration are controversial. We treated four RPE65-mutant dogs in mid-life (age = 5-6 years) and followed them long-term (4-5 years). At the time of the intervention at mid-life, there were intra-ocular and inter-animal differences in local photoreceptor layer health ranging from near normal to complete degeneration. Treated locations having more than 63% of normal photoreceptors showed robust treatment-related retention of photoreceptors in the long term. Treated regions with less retained photoreceptors at the time of the intervention showed progressive degeneration similar to untreated regions with matched initial stage of disease. Unexpectedly, both treated and untreated regions in study eyes tended to show less degeneration compared to matched locations in untreated control eyes. These results support the hypothesis that successful long-term arrest of progression with RPE65 gene therapy may only occur in retinal regions with relatively retained photoreceptors at the time of the intervention, and there may be heretofore unknown mechanisms causing long-distance partial treatment effects beyond the region of subretinal injection.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Rhodopsin Antibody, Chemicon®, from rabbit
SKU
Pack Size
Availability
Price
Quantity